How does BLENREP work?
BLENREP is a targeted cancer therapy known as an antibody-drug conjugate. It combines two components that work together to find and destroy myeloma cells:
- Belantamab is a monoclonal antibody that sticks to a protein called BCMA (B-cell maturation antigen) found on multiple myeloma cells. This helps the medicine get to the right place in the body and stick to the myeloma cell.
- Mafodotin, an anticancer substance that can kill multiple myeloma cells.
What is given in combination with BLENREP?
BLENREP can be given in two combinations
- Blenrep, in combination with Bortezomib and Dexamethasone (BVd).
OR
- Blenrep, in combination with Pomalidomide and Dexamethasone (BPd).
If you are unsure what combination you are on, ask your cancer care team
If you experience any side effects, talk to your doctor, nurse or pharmacist. This includes any possible side effects not listed in the package leaflet.
You can also report side effects directly via the Yellow Card Scheme at: https://yellowcard.mhra.gov.uk or search for MHRA Yellow Card in the Google Play or Apple App Store. By reporting side effects, you can help provide more information on the safety of this medicine. Adverse events should also be reported to GlaxoSmithKline on 0800 221 441 or uksafety@gsk.com.
▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See information in paragraph above to see how to report side effects.
BLENREP is a registered trademark of the GlaxoSmithKline group of companies
